Cargando…
Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension
Cirrhosis and idiopathic portal hypertension (IPH) are 2 major diseases showing portal hypertension. However, characteristics and outcomes of IPH with ascites have not yet been determined. The aim of the study was to examine the influence of ascites on the long-term clinical course of IPH. This obse...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504543/ https://www.ncbi.nlm.nih.gov/pubmed/26131820 http://dx.doi.org/10.1097/MD.0000000000001056 |
_version_ | 1782381480520974336 |
---|---|
author | Maruyama, Hitoshi Kondo, Takayuki Sekimoto, Tadashi Yokosuka, Osamu |
author_facet | Maruyama, Hitoshi Kondo, Takayuki Sekimoto, Tadashi Yokosuka, Osamu |
author_sort | Maruyama, Hitoshi |
collection | PubMed |
description | Cirrhosis and idiopathic portal hypertension (IPH) are 2 major diseases showing portal hypertension. However, characteristics and outcomes of IPH with ascites have not yet been determined. The aim of the study was to examine the influence of ascites on the long-term clinical course of IPH. This observational study compared the long-term clinical findings including portal hemodynamics demonstrated by Doppler ultrasonography between 166 cirrhosis (87 males and 79 females; mean age ± standard deviation, 62.5 ± 11.8 years; age range, 20–89 years) and 14 IPH patients (3 males and 11 females; mean age ± standard deviation, 64.2 ± 6.6 years; age range, 51–78 years). Both groups comprised of consecutive patients from November 2007 through February 2013 and were studied retrospectively. The median observation period was 33.4 months for ascites and 34.5 months for survival. Ascites was detected in 60/166 (36.1%) and 116/166 (69.9%) cirrhosis patients and in 7/14 (50%) and 9/14 (64.3%) IPH patients, at baseline and at the end of the observation period, respectively. The cumulative incidence of ascites was 12.3% at 1 year, 35.9% at 3 years, and 59.9% at 5 years in cirrhosis, and 25% at 3 years, and 50% at 5 years in IPH (P = 0.36). Deterioration of ascites in patients showing mild ascites at baseline was found in 32.4% of cirrhosis patients and 42.9% of IPH patients (P = 0.41). Serum creatinine (mg/dl) at baseline was significantly higher in IPH patients who developed ascites (n = 2, 0.74 ± 0.14) than in those who did not (n = 5, 0.526 ± 0.06, P = 0.029). The overall survival rate appeared to favor IPH (100% at 1 year, 92.9% at 3 and 5 years; P = 0.2) more than cirrhosis (87.7% at 1 year, 75.2% at 3 years, and 63.6% at 5 years), but did not reach statistical significance. However, in patients with ascites at baseline, the survival rate was significantly better in IPH (100% at 1, 3, and 5 years, P = 0.04) than in cirrhosis (69.1% at 1 year, 43% at 3 years, 34.4% at 5 years). The presence of ascites at baseline correlated with worse survival rates in patients with cirrhosis as compared to those with IPH as the underlying etiology. |
format | Online Article Text |
id | pubmed-4504543 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-45045432015-08-05 Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension Maruyama, Hitoshi Kondo, Takayuki Sekimoto, Tadashi Yokosuka, Osamu Medicine (Baltimore) 4500 Cirrhosis and idiopathic portal hypertension (IPH) are 2 major diseases showing portal hypertension. However, characteristics and outcomes of IPH with ascites have not yet been determined. The aim of the study was to examine the influence of ascites on the long-term clinical course of IPH. This observational study compared the long-term clinical findings including portal hemodynamics demonstrated by Doppler ultrasonography between 166 cirrhosis (87 males and 79 females; mean age ± standard deviation, 62.5 ± 11.8 years; age range, 20–89 years) and 14 IPH patients (3 males and 11 females; mean age ± standard deviation, 64.2 ± 6.6 years; age range, 51–78 years). Both groups comprised of consecutive patients from November 2007 through February 2013 and were studied retrospectively. The median observation period was 33.4 months for ascites and 34.5 months for survival. Ascites was detected in 60/166 (36.1%) and 116/166 (69.9%) cirrhosis patients and in 7/14 (50%) and 9/14 (64.3%) IPH patients, at baseline and at the end of the observation period, respectively. The cumulative incidence of ascites was 12.3% at 1 year, 35.9% at 3 years, and 59.9% at 5 years in cirrhosis, and 25% at 3 years, and 50% at 5 years in IPH (P = 0.36). Deterioration of ascites in patients showing mild ascites at baseline was found in 32.4% of cirrhosis patients and 42.9% of IPH patients (P = 0.41). Serum creatinine (mg/dl) at baseline was significantly higher in IPH patients who developed ascites (n = 2, 0.74 ± 0.14) than in those who did not (n = 5, 0.526 ± 0.06, P = 0.029). The overall survival rate appeared to favor IPH (100% at 1 year, 92.9% at 3 and 5 years; P = 0.2) more than cirrhosis (87.7% at 1 year, 75.2% at 3 years, and 63.6% at 5 years), but did not reach statistical significance. However, in patients with ascites at baseline, the survival rate was significantly better in IPH (100% at 1, 3, and 5 years, P = 0.04) than in cirrhosis (69.1% at 1 year, 43% at 3 years, 34.4% at 5 years). The presence of ascites at baseline correlated with worse survival rates in patients with cirrhosis as compared to those with IPH as the underlying etiology. Wolters Kluwer Health 2015-07-02 /pmc/articles/PMC4504543/ /pubmed/26131820 http://dx.doi.org/10.1097/MD.0000000000001056 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0, where it is permissible to download, share and reproduce the work in any medium, provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | 4500 Maruyama, Hitoshi Kondo, Takayuki Sekimoto, Tadashi Yokosuka, Osamu Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension |
title | Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension |
title_full | Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension |
title_fullStr | Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension |
title_full_unstemmed | Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension |
title_short | Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension |
title_sort | differential clinical impact of ascites in cirrhosis and idiopathic portal hypertension |
topic | 4500 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504543/ https://www.ncbi.nlm.nih.gov/pubmed/26131820 http://dx.doi.org/10.1097/MD.0000000000001056 |
work_keys_str_mv | AT maruyamahitoshi differentialclinicalimpactofascitesincirrhosisandidiopathicportalhypertension AT kondotakayuki differentialclinicalimpactofascitesincirrhosisandidiopathicportalhypertension AT sekimototadashi differentialclinicalimpactofascitesincirrhosisandidiopathicportalhypertension AT yokosukaosamu differentialclinicalimpactofascitesincirrhosisandidiopathicportalhypertension |